~33% ORR by RECIST 1.1: 1 CR + 8 PRs out of 27 evaluable heavily pre-treated (median 2-3 prior lines, ranging from 1-7) MTAP-deletion UC and NSCLC patients 9 of 9 responses have confirmed by...

GTCHAIR rocked the stage at the 2024 ORGATEC furniture exhibition in Cologne, Germany. Their booth, located at Hall 8.1 A060, showcased a cool range of office chairs that make sitting comfy and...

On October 24, 2024, TASTE-2, a Chinese innovative stroke drug study led by Professor Wang Yongjun from Beijing Tiantan Hospital, was published in an oral report at the 16th World Stroke...

A news report from chinadaily.com.cn： The 2024 World Internet Conference (WIC) Wuzhen Summit, which is set to take place from Nov 19 to 22 in Wuzhen, East China's Zhejiang province, will focus...

- Encouraging preliminary anti-tumor activity observed in heavily pre-treated population - - At ≥ 90 mg QD, 6 out of 11 (54.5%) patients with FGFR3+ mUC achieved a confirmed partial response...